Changeflow GovPing Healthcare & Life Sciences Methods for Gene Training
Priority review Rule Added Final

Methods for Gene Training

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

MendAGene LLC, through inventor Edward Jason Stanek, filed USPTO patent application US20260112451A1 on June 20, 2025 (Application No. 19244001) covering methods for gene training to digitally adjust protein expression levels in organisms. The application publication discloses methods applicable to improving human health, animal health, crop health, carbon capture, agricultural productivity, and biologics development. The invention addresses challenges in precise protein expression control including limited ability to control experimental factors, measurement limitations, and prediction accuracy when modifying transcription factors, promoters, and GC content.

“This disclosure introduces methods of gene training to help enable more direct, expedient and successful product development pipelines to digitally adjust or aim expression level of one or more proteins, such as for improving crops, carbon capture, biologics, research and development, and human health.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 264 changes logged to date.

What changed

USPTO published patent application US20260112451A1 disclosing methods for gene training to digitally adjust or aim expression levels of one or more proteins in an organism. The application covers applications including improving crops, carbon capture, biologics, research and development, and human health. The invention addresses challenges in precisely changing protein expression due to limited ability to control experimental factors, measurement limitations, the exponential number of ways to affect gene expression, and limited precision and accuracy in predicting changes when modifying transcription factors, promoters, and GC content.

Companies in the biotechnology, pharmaceutical, and agricultural sectors conducting protein expression work should monitor this application for potential patent scope implications. As a pending application, the claims have not yet undergone substantive USPTO examination and the final granted scope could differ materially from the published application.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

METHODS FOR GENE TRAINING

Application US20260112451A1 Kind: A1 Apr 23, 2026

Assignee

MendAGene LLC

Inventors

Edward Jason STANEK

Abstract

Specific proteins catalyze specific reactions, transport specific molecules, and form specific cellular structures and changing their presence and relative abundance can be applied, for example to improve human health, animal health, crop health, carbon capture, agricultural productivity and protection, and biologic activity. However, precisely effectuating phenotypic changes and outcomes is expensive and error prone; and precisely changing protein expression in an organism has been challenging due to limited ability to control experimental factors, limitations of measurement, the exponential number of ways to affect gene expression of a protein, and limited precision and accuracy in predicting changes to expression when modifying transcription factors, promoters, and GC content. This disclosure introduces methods of gene training to help enable more direct, expedient and successful product development pipelines to digitally adjust or aim expression level of one or more proteins, such as for improving crops, carbon capture, biologics, research and development, and human health.

CPC Classifications

G16B 30/00 C12N 15/113 G16B 20/20 G16H 50/20 C12N 2310/11

Filing Date

2025-06-20

Application No.

19244001

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Biotechnology firms
Industry sector
3254.1 Biotechnology 3254 Pharmaceutical Manufacturing 2210 Electric Utilities
Activity scope
Patent application filing Biotechnology research Protein expression methods
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Biotechnology Healthcare Agriculture

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!